Open AccessApolipoprotein A‐IV is an independent predictor of disease activity in patients with inflammatory bowel disease
Author(s) -
Broedl Uli C.,
Schachinger Veronika,
Lingenhel Arno,
Lehrke Michael,
Stark Renee,
Seibold Frank,
Göke Burkhard,
Kronenberg Florian,
Parhofer Klaus G.,
KonradZerna Astrid
Publication year - 2007
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1002/ibd.20078
Subject(s) - inflammatory bowel disease , medicine , odds ratio , univariate analysis , gastroenterology , ulcerative colitis , confidence interval , disease , logistic regression , apolipoprotein b , crohn's disease , immunology , cholesterol , multivariate analysis
Background: ApoA‐IV, an apolipoprotein (apo) with antioxidant, antiatherogenic, and antiinflammatory properties, was recently demonstrated to inhibit dextran sulfate sodium (DSS)‐induced experimental colitis in mice. We therefore hypothesized that apoA‐IV may be associated with disease activity in patients with inflammatory bowel disease (IBD). Methods: We addressed this question by testing for associations between apoA‐IV genotypes, apoA‐IV plasma levels, inflammatory parameters, and clinical disease activity in 206 patients with Crohn's disease (CD), 95 subjects with ulcerative colitis (UC), and 157 healthy controls. Results: In CD patients, apoA‐IV plasma levels were inversely associated with C‐reactive protein (CRP) ( P = 0.005) and disease activity ( P = 0.01) in univariate analysis. In multiple logistic regression analysis, apoA‐IV levels were identified as an independent predictor of elevated CRP (odds ratio [OR] 0.956, 95% confidence interval [CI]: 0.916–0.998, P = 0.04) and active disease (OR 0.957, 95% CI: 0.918–0.998, P = 0.04). In UC patients the apoA‐IV gene variant 360 His ( P = 0.03) but not apoA‐IV levels ( P = 0.15) were associated with increased disease activity in univariate analysis. This association, however, was lost in multiple logistic regression analysis (OR 3.435, 95% CI 0.995–11.853, P = 0.05). Conclusions: To our knowledge, this is the first study to demonstrate an association of apoA‐IV with disease activity in patients with CD. Further studies are needed to define the relationship of apoA‐IV to IBD. (Inflamm Bowel Dis 2007)